301 related articles for article (PubMed ID: 23404788)
1. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
Henry RR; Mudaliar S; Kanitra L; Woloschak M; Balena R;
J Clin Endocrinol Metab; 2012 Jul; 97(7):2370-9. PubMed ID: 22539590
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
Nauck MA; Ratner RE; Kapitza C; Berria R; Boldrin M; Balena R
Diabetes Care; 2009 Jul; 32(7):1237-43. PubMed ID: 19366970
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
Raz I; Fonseca V; Kipnes M; Durrwell L; Hoekstra J; Boldrin M; Balena R
Diabetes Care; 2012 Mar; 35(3):485-7. PubMed ID: 22301126
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Pratley RE; Urosevic D; Boldrin M; Balena R;
Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
[TBL] [Abstract][Full Text] [Related]
8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
9. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
Gastaldelli A; Nauck MA; Balena R
Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
[TBL] [Abstract][Full Text] [Related]
10. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
Jacob S; Rabbia M; Meier MK; Hauptman J
Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
Ratner R; Nauck M; Kapitza C; Asnaghi V; Boldrin M; Balena R
Diabet Med; 2010 May; 27(5):556-62. PubMed ID: 20536952
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
13. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
15. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Kopelman P; Groot Gde H; Rissanen A; Rossner S; Toubro S; Palmer R; Hallam R; Bryson A; Hickling RI
Obesity (Silver Spring); 2010 Jan; 18(1):108-15. PubMed ID: 19461584
[TBL] [Abstract][Full Text] [Related]
16. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
[TBL] [Abstract][Full Text] [Related]
18. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
